Hagens Berman was appointed co-lead counsel in this pharmaceutical fraud class-action lawsuit against Schering-Plough (NYSE: SGP) and Merck (NYSE: MRK), in which the class claimed the companies knowingly misled consumers on the use of popular prescription drugs Zetia and Vytorin.
The case was filed on Jan. 17, 2008 in the U.S. District Court in New Jersey. Judge Dennis Cavanaugh approved and ordered an organizational structure consisting of five law firms to comprise a Plaintiffs Steering Committee which is responsible for coordinating plaintiffs during pretrial proceedings and more. The lawsuit claims Schering-Plough and Merck violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin.
Zetia is a brand-name prescription drug used to lower LDL levels by decreasing cholesterol absorption in the intestinal tract. Vytorin is a combination of Zetia and Zocor, a statin available in generic form.
The suit claims that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial plaques that can cause heart attack and stroke, as the manufacturers led consumers to believe since 2006. The companies promoted Zetia heavily, claiming that by adding it to statin treatment, patients could more effectively lower LDL cholesterol which would, in turn, reduce plaque in patients' arteries, according to their advertisements. According to the complaint, the companies had prior information that refuted that claim.
The Vytorin/Zetia Fraud Case is In Re: Vytorin/Zetia Marketing, Sales Practices and Products Liability Litigation, MDL Case No. 193, U.S. District Court for the District of New Jersey.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.